NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

BillionToOne, Inc. (BLLN) Stock Analysis

BillionToOne, Inc. (BLLN) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BLLN

$104.67

+$1.17 (+1.13%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLLN with… →

BLLN Key Statistics

As of Oct 21, 2026
Trading
Open
$103.27
Previous Close
$103.50
Day's Range
102.80–107.04
52-Week Range
61.96–150.44
Volume
358.31K
Valuation
Market Cap
$4.62B
P/E Ratio
148.30
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
65.91
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.62
EPS (ttm)Profit attributable to each share over the last twelve months.
0.66
Financials (FY)
Revenue (FY)
$305.11M
Net Income (FY)
$7.45M
Profit marginThe share of revenue left as profit after all costs and taxes.
8.35%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
42.64M
1-Year Return
−3.92%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
681.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BLLN closed at $104.67, −3.92% over 1 year.

BillionToOne, Inc. (BLLN) has a market capitalization of $4.62B.

BLLN Stock Return by Calendar Year

BillionToOne, Inc. (BLLN) return since Nov 2025: what $10,000 became

1 year
$10,000 $9,608
−3.92%

If you had invested $10,000 in BillionToOne, Inc. (BLLN) at the close on November 6, 2025, the earliest close on record here, it would have been worth $9,608 at the close on October 21, 2026: −3.92% in total, −3.92% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+27.90%
2025 (partial year)−24.88%

As of October 21, 2026.

BLLN Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricBLLNDiagnostics & Research medianvs median
P/E148.3037.593.9x the median
P/S ratio11.625.23122% above
Profit margin8.35%−0.93%9.3 pts above

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values BillionToOne, Inc. (BLLN) at $4.62B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 713.

Over the past 52 weeks the price has ranged from $61.96 to $150.44. The most recent close on file for BLLN is $104.67, dated October 21, 2026. That is +$1.17 (+1.13%) against the previous close. The latest close sits 68.93% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $305.11M. The same year closed with net income of $7.45M. The reported profit margin is 8.35%. That is 9.3 percentage points above the Diagnostics & Research median of −0.93%. Trailing earnings per share are 0.66.

Valuation Assessment

On trailing earnings, the shares are priced at 148.3 times earnings. That is 3.9 times the Diagnostics & Research median of 37.59. On forward earnings the ratio is 65.91. Measured against sales, the shares trade at 11.62 times revenue. On price-to-sales that is 122.35% above the Diagnostics & Research median of 5.23. The medians here are taken across 45 Diagnostics & Research companies that report the metric.

The trailing one-year total return is −3.92%. Annualized volatility over the trailing 1 year is 89.48%.

Growth & Income

The record shows no dividend for BLLN.

2026 is still running; the total return is +27.90% year to date.

Peer Comparison

BillionToOne, Inc. (BLLN) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BillionToOne, Inc. BLLN $4.62B 148.3
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. BillionToOne, Inc. trades at a P/E of 148.3.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BillionToOne, Inc.

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Visit website →